RT Journal Article
SR Electronic
T1 Differences in antibody kinetics and functionality between severe and mild SARS-CoV-2 infections
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.09.20122036
DO 10.1101/2020.06.09.20122036
A1 Rijkers, Ger
A1 Murk, Jean-Luc
A1 Wintermans, Bas
A1 Looy, Bieke van
A1 van den Berge, Marcel
A1 Veenemans, Jacobien
A1 Stohr, Joep
A1 Reusken, Chantal
A1 van der Pol, Pieter
A1 Reimerink, Johan
YR 2020
UL http://medrxiv.org/content/early/2020/06/12/2020.06.09.20122036.abstract
AB We determined and compared the humoral immune response in severe, hospitalized and mild, non-hospitalized COVID-19 patients. Severe patients (n=38) develop a robust antibody response to SARS-CoV-2, including IgG and IgA antibodies. The geometric mean 50% virus neutralization titer is 1:240. SARS-CoV-2 infected hospital personnel (n=24), who developed mild symptoms necessitating leave of absence, self-isolation, but not hospitalization, 75 % develop antibodies, but with low/absent virus neutralization (60% < 1:20).While severe COVID-19 patients develop a strong antibody response, mild SARS-CoV-2 infections induce a modest antibody response. Long term monitoring will show whether these responses predict protection against future infections.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Exemption for the research was provided by Medisch ethische toetsingscommissie Brabant (Medical Ethical Committee Brabant) PO Box 90151, 5000 LC Tilburg The Netherlands info@metcbrabantnlAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesnot applicable